Charles Schwab Investment Management Inc. Has $33.27 Million Stake in Roivant Sciences Ltd. (NASDAQ:ROIV)

Charles Schwab Investment Management Inc. raised its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 1.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,812,502 shares of the company's stock after acquiring an additional 45,090 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.39% of Roivant Sciences worth $33,272,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the business. FMR LLC increased its stake in Roivant Sciences by 5.6% during the 3rd quarter. FMR LLC now owns 49,145,056 shares of the company's stock valued at $567,134,000 after buying an additional 2,593,910 shares during the period. State Street Corp raised its holdings in Roivant Sciences by 6.1% during the third quarter. State Street Corp now owns 19,561,249 shares of the company's stock worth $225,737,000 after purchasing an additional 1,118,561 shares in the last quarter. Geode Capital Management LLC lifted its position in Roivant Sciences by 23.2% in the third quarter. Geode Capital Management LLC now owns 7,745,104 shares of the company's stock worth $89,400,000 after purchasing an additional 1,460,205 shares during the period. TOMS Capital Investment Management LP bought a new position in Roivant Sciences during the 3rd quarter valued at $46,333,000. Finally, Loomis Sayles & Co. L P increased its position in shares of Roivant Sciences by 13.3% during the 3rd quarter. Loomis Sayles & Co. L P now owns 3,912,205 shares of the company's stock valued at $45,147,000 after purchasing an additional 458,601 shares during the period. Institutional investors own 64.76% of the company's stock.

Remove Ads

Roivant Sciences Trading Up 1.8 %

ROIV stock traded up $0.19 during mid-day trading on Monday, reaching $10.85. 5,225,228 shares of the stock traded hands, compared to its average volume of 5,484,257. The stock's fifty day moving average is $10.81 and its 200-day moving average is $11.50. The company has a market cap of $7.74 billion, a P/E ratio of -72.33 and a beta of 1.26. Roivant Sciences Ltd. has a 52-week low of $9.76 and a 52-week high of $13.06.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last issued its earnings results on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, beating analysts' consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. Equities research analysts expect that Roivant Sciences Ltd. will post -0.92 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on ROIV. Cantor Fitzgerald raised Roivant Sciences to a "strong-buy" rating in a research note on Tuesday, March 4th. HC Wainwright reaffirmed a "buy" rating and issued a $18.00 price objective on shares of Roivant Sciences in a research note on Tuesday, February 11th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $18.08.

Insider Buying and Selling

In related news, Director Sciences Ltd. Roivant bought 16,845,010 shares of the company's stock in a transaction that occurred on Monday, January 13th. The shares were acquired at an average price of $20.00 per share, with a total value of $336,900,200.00. Following the completion of the transaction, the director now owns 96,650,341 shares of the company's stock, valued at $1,933,006,820. The trade was a 21.11 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CIO Mayukh Sukhatme sold 412,584 shares of the company's stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $12.05, for a total transaction of $4,971,637.20. Following the transaction, the executive now directly owns 18,836,547 shares of the company's stock, valued at $226,980,391.35. This represents a 2.14 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 2,388,170 shares of company stock worth $27,612,299. Insiders own 7.90% of the company's stock.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.